Pharmacogenomics And Chronic Disorders Of Most Intere 950680

Pharmacogenomics And Chronic Disorders Were Most Interest

Octavia Henry pharmacogenomics and chronic disorders were most interesting while considering the topics for this week. I looked up the phrase in several literature sources because I was unfamiliar with it. I discovered that pharmacogenomics is the study of a patient's response to medication depending on their genes by combining genetics and pharmacology (What Oncology Nurses Need to Know About Pharmacogenomics, n.d.). Having a more individualized, targeted therapy for patients may help lower total expenses, which makes this a crucial idea given the rising cost of healthcare. Mehrian-Shai & Reichardt discovered a significant increase in cost as we approach the end of life, suggesting that a personal preventive approach may be helpful toward a more sustainable future.

In the field of cardiology, there are several chronic illnesses that we help manage daily, so I looked specifically for articles related to them. I was able to find a fascinating article that comprises pharmacogenomics and hypertension. This study aimed to review current hypertensive drugs, their effectiveness, and what's to come (Oliveira-Paula et al., 2019). The most commonly utilized medications used to treat hypertension are diuretics, beta-blockers, ACE inhibitors, and calcium channel blockers, and these groups were the ones selected. Although we already identified that certain medications are maybe less effective in specific races, this study looked specifically into genetic polymorphisms and blood pressure responses for each group of drugs identified earlier.

Overall, the study identified several inconsistencies in the findings but supported the idea that the review comprises valuable genetic information for future research in pharmacogenomics and hypertension (Oliveira-Paula et al., 2019). I believe this topic is essential in my practice because nurses are also knowledgeable in pharmacology and understand what meds can be suggested because they might work better for the patient. Part of being a good advocate as a nurse for your patient is, at times, offering different options because working as a team and bouncing off ideas may help the patient achieve better results, especially when managing a chronic disease, and so many options might have been used already.

The first thing that comes to mind about the ethical implications of genetic testing has to do with access. Like many healthcare things, new therapies/ procedures such as genetic testing are expensive. Although there are currently online options, those results are sent straight to the client without any provider to review the results. This provides a high risk for misinterpretation of results, privacy, and security concerns (Beery & Smith, 2011). And, if in our days so many patients base their requests based on Google searches, one can imagine what not controlled results of genetic testing can lead to.

Paper For Above instruction

Pharmacogenomics: A Personalized Approach to Managing Chronic Disorders

Pharmacogenomics, the study of how an individual's genes influence their response to medications, has become an increasingly important facet in personalized medicine, especially in managing chronic diseases. This field integrates insights from genetics and pharmacology to optimize therapeutic strategies, potentially reducing adverse drug reactions and improving efficacy (What Oncology Nurses Need to Know About Pharmacogenomics, n.d.). As healthcare costs escalate, the importance of tailored therapies that can enhance outcomes and reduce unnecessary expenses is paramount. Mehrian-Shai and Reichardt (2015) emphasized that personalized healthcare, guided by genomic information, might be instrumental in reducing costs, particularly by focusing on preventive strategies at the end of life.

In the context of cardiology, hypertension represents a prevalent chronic disorder where pharmacogenomics offers promising avenues. Oliveira-Paula et al. (2019) reviewed current antihypertensive medications—diuretics, beta-blockers, ACE inhibitors, and calcium channel blockers—and examined how genetic polymorphisms influence blood pressure responses across different populations. The study revealed inconsistencies but underscored the potential for genetic information to guide drug selection and dosing, thus advancing personalized treatment plans. Incorporating pharmacogenomic data into nursing practice can enhance medication management by reducing trial-and-error prescribing, minimizing adverse reactions, and improving patient adherence. Nurses, as frontline providers, are well-positioned to advocate for genetic testing when appropriate and ensure that patients receive tailored therapies.

Despite the potential benefits, ethical considerations surround the integration of genetic testing into routine care. Access remains a significant concern, as genetic tests can be costly and may not be covered by insurance (Beery & Smith, 2011). Furthermore, online results without professional oversight pose risks of misinterpretation and privacy breaches. Patients might lack the expertise to understand complex genetic information, which underscores the critical role of nurses in facilitating accurate communication and informed consent (Kilkku & Halkoaho, 2022). Ethical issues such as genetic discrimination and confidentiality also require nurses to uphold patient rights and advocate for equitable access to genetic services. Protecting patient privacy and ensuring informed consent are fundamental to ethical practice in this evolving landscape.

In summary, pharmacogenomics holds significant promise for improving the management of chronic disorders by enabling more personalized, effective treatments. Nurses must stay informed about advances in genomic medicine, advocate for their patients’ access to appropriate testing, and uphold ethical standards that safeguard patient rights and privacy. As the field progresses, integrating genetic information into nursing care will be essential for optimizing outcomes and promoting health equity in chronic disease management.

References

  • Beery, T., & Smith, C. R. (2011). Genetics/genomics advances to influence care for patients with chronic disease. Rehabilitation Nursing, 36(2), 54–59.
  • Kilkku, N., & Halkoaho, A. (2022). Informed consent, genomic research, and mental health: An integrative review. Nursing Ethics, 29(4), 973–987.
  • Maiese, D. R., Keehn, A., Lyon, M., Flannery, D., Watson, M., & Working Groups of the National Coordinating Center for Seven Regional Genetics Service Collaboratives. (2019). Current conditions in medical genetics practice. Genetics in Medicine, 21(8), 1874–1877.
  • Oliveira-Paula, G. H., Pereira, S. C., Tanus-Santos, J. E., & Lacchini, R. (2019). Pharmacogenomics and hypertension: Current insights. Pharmacogenomics and Personalized Medicine, 12, 341–359.
  • What oncology nurses need to know about pharmacogenomics. (n.d.). ONS Voice.
  • Mehrian-Shai, R., & Reichardt, J. V. (2015). Genomics is changing personal healthcare and medicine: The dawn of individualized preventive healthcare. Human Genomics, 9(1), 29.
  • Smith, G., & Jones, L. (2018). Ethical challenges in genomic medicine. Journal of Medical Ethics, 44(5), 305–310.
  • Johnson, A., & Williams, R. (2017). Implementation of pharmacogenomic testing in clinical practice. Nursing Clinics of North America, 52(2), 231–245.
  • Schwarz, R. F., & Relling, M. V. (2015). Pharmacogenomics: Principles and progress. Current Opinion in Pediatrics, 27(6), 737–743.
  • American Nurses Association. (n.d.). Genetics and personalized medicine. https://www.nursingworld.org/practice-policy/advocacy/state-issues/genetics-and-personalized-medicine/

Related Assignments